Trial Profile
The safety, tolerability and pharmacokinetics (plasma and urine) of a single intravenous infusion of 20, 70, 200, 400 and 700 µg/kg XG-104 administered to healthy male volunteers in a randomized, double-blind, placebo-controlled, dose escalating Phase I study
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Sep 2014
Price :
$35
*
At a glance
- Drugs XG 104 (Primary)
- Indications Dry eyes
- Focus Adverse reactions
- Sponsors Xigen
- 22 Sep 2014 New trial record